Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Angiogenic Endothelial Cell (via PPE1–3x Promoter-driven Chimeric Death Receptor)
- Molecular classification
- Cell, Transcriptionally Targeted Therapy, Chimeric Receptor
01
Overview
An angiogenic endothelial cell is an endothelial cell actively participating in the process of angiogenesis. This target refers specifically to angiogenic endothelial cells expressing a chimeric death receptor gene driven by the PPE1–3x promoter, enabling selective targeting of activated, angiogenic endothelium in pathological conditions such as tumor angiogenesis. The PPE1-3x promoter's specificity allows for localized induction of apoptosis upon activation of the chimeric death receptor.
- Other names
- Activated Endothelial Cell (PPE1-3x-Chimeric Death Receptor)Tumor Endothelial Cell (PPE1-3x-Chimeric Death Receptor)
02
Mechanism of action
PPE1–3x promoter drives expression of a chimeric death receptor (e.g., Fas-c) selectively in angiogenic endothelial cells; ligand binding (e.g., by TNFα or FasL) triggers apoptosis.
03
Biological functions
AngiogenesisApoptosis inductionTumor vasculature targeting
04
Disease associations
CancerTumor angiogenesisMetastasis
05
Safety considerations
Off-target effects (limited by promoter specificity)Immune response to viral vector (if used for delivery)Cytokine release syndrome (potential with death receptor activation)
06
Interacting drugs
VB-111 (clinical trials)
2 more in the full profile.
07
Biomarkers
PPE1–3x promoter activity (angiogenesis level)Endothelial cell markers (e.g., CD31, VE-cadherin)
Beyond the preview
Go deeper on Angiogenic Endothelial Cell (via PPE1–3x Promoter-driven Chimeric Death Receptor).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Angiogenic Endothelial Cell (via PPE1–3x Promoter-driven Chimeric Death Receptor).